
handle: 10334/9188
Trabajo Fin de Máster en Alergia a Fármacos (2022-23). Tutora: Dra. Dª. Cristobalina Mayorga. Debido al progresivo aumento de pacientes oncológicos de forma directa también lo ha hecho la incidencia de éstos con hipersensibilidad a agentes antineoplásicos. Estas reacciones representan un problema muy importante para los pacientes que no pueden prescindir de fármacos esenciales para su supervivencia. La desensibilización a medicamentos ha permitido la administración de fármacos de primera línea en pacientes con reacciones de hipersensibilidad a quimioterápicos de manera segura y altamente efectiva. Aunque no está exenta de riesgos, las reacciones observadas durante la desensibilización suelen ser leves, considerándose infrecuentes las reacciones moderadas o graves. Lo que hace que el balance riesgo beneficio se decante a favor de su realización. Existen diferentes protocolos que han demostrado su eficacia, en este trabajo describimos nuestra experiencia con el uso de un protocolo de 12 pasos en tres bolsas de soluciones diluidas 10 veces (1:100, 1:10 y 1:1).
: Due to the progressive increase in oncological patients, there has been a corresponding rise in the incidence of hypersensitivity to antineoplastic agents. These reactions represent an important burden for the patients who cannot survivsurvive without these essential drugsdrugs. Drug desensitization has enabled the administration of first first-line medications in patients with hypersensitivity reactions to chemotherapy. Desensitization is a safe and highly effective procedure. While not without risks, the reactio ns observed during desensitization are typically mild, with moderate to severe reactions being rare. This makes the risk risk-benefit balance lean in favour of its performance . There are different protocols that have proven effective effective, in this study, we describe our experience using a 12 12-step protocol in three bags of solutions diluted tenfold (1:100, 1:10, and 1:1).
18 páginas.
Hospital Reina Sofía de Córdoba (España), Oxaliplatino, Carboplatino, 610, Hipersensibilidad a fármacos, Quimioterápicos, Cáncer
Hospital Reina Sofía de Córdoba (España), Oxaliplatino, Carboplatino, 610, Hipersensibilidad a fármacos, Quimioterápicos, Cáncer
| selected citations These citations are derived from selected sources. This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically). | 0 | |
| popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network. | Average | |
| influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically). | Average | |
| impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network. | Average |
